CZ20033195A3 - Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití - Google Patents

Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití Download PDF

Info

Publication number
CZ20033195A3
CZ20033195A3 CZ20033195A CZ20033195A CZ20033195A3 CZ 20033195 A3 CZ20033195 A3 CZ 20033195A3 CZ 20033195 A CZ20033195 A CZ 20033195A CZ 20033195 A CZ20033195 A CZ 20033195A CZ 20033195 A3 CZ20033195 A3 CZ 20033195A3
Authority
CZ
Czechia
Prior art keywords
formula
indole
compound
solvates
group
Prior art date
Application number
CZ20033195A
Other languages
Czech (cs)
English (en)
Inventor
Kai Schiemann
Henning Böttcher
Joachim Leibrock
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CZ20033195A3 publication Critical patent/CZ20033195A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CZ20033195A 2001-04-30 2002-03-30 Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití CZ20033195A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10121215A DE10121215A1 (de) 2001-04-30 2001-04-30 Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden

Publications (1)

Publication Number Publication Date
CZ20033195A3 true CZ20033195A3 (cs) 2004-02-18

Family

ID=7683301

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20033195A CZ20033195A3 (cs) 2001-04-30 2002-03-30 Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití

Country Status (13)

Country Link
US (1) US7279496B2 (https=)
EP (1) EP1383774B1 (https=)
JP (1) JP4593879B2 (https=)
AR (1) AR033624A1 (https=)
AT (1) ATE394404T1 (https=)
AU (1) AU2002310904B2 (https=)
CA (1) CA2445834C (https=)
CZ (1) CZ20033195A3 (https=)
DE (2) DE10121215A1 (https=)
ES (1) ES2303857T3 (https=)
HU (1) HUP0304046A2 (https=)
SK (1) SK14472003A3 (https=)
WO (1) WO2002088143A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656093A (zh) * 2002-05-30 2005-08-17 神经研究公司 3－取代的奎宁环及其用途
US20050171079A1 (en) * 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
ZA200709038B (en) * 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
US7897766B2 (en) * 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
CN101466709B (zh) * 2006-04-13 2013-03-20 轴突公司 具有nos抑制活性的1,5和3,6-取代的吲哚化合物
EA201000808A1 (ru) * 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
EP2219449A4 (en) * 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
WO2009062318A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
FR3165598A1 (fr) 2024-08-14 2026-02-20 Ultrawatt Élément d’habillage d’une paroi et kit comportant au moins un tel élément

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009565A1 (de) 1990-03-24 1991-09-26 Merck Patent Gmbh Indolderivate
ATE157977T1 (de) * 1992-10-13 1997-09-15 Warner Lambert Co Chinoxalinderivate als eaa antagonisten
US5843945A (en) 1993-05-13 1998-12-01 Neurosearch A/S AMPA antagonists and a method of treatment
WO1994026747A1 (en) 1993-05-13 1994-11-24 Neurosearch A/S Ampa antagonists and a method of treatment therewith
AU727608B2 (en) * 1995-10-03 2000-12-14 Scripps Research Institute, The CBI analogs of CC-1065 and the duocarmycins
US6147096A (en) * 1998-02-26 2000-11-14 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrrolobenzimidazoles for treating inflammatory diseases

Also Published As

Publication number Publication date
JP4593879B2 (ja) 2010-12-08
HUP0304046A2 (hu) 2004-04-28
DE10121215A1 (de) 2002-10-31
DE60226428D1 (de) 2008-06-19
JP2004529936A (ja) 2004-09-30
EP1383774B1 (en) 2008-05-07
EP1383774A2 (en) 2004-01-28
ATE394404T1 (de) 2008-05-15
SK14472003A3 (sk) 2004-04-06
AU2002310904B2 (en) 2008-01-10
US20040142935A1 (en) 2004-07-22
WO2002088143A2 (en) 2002-11-07
AR033624A1 (es) 2003-12-26
WO2002088143A3 (en) 2003-01-23
CA2445834C (en) 2011-06-28
ES2303857T3 (es) 2008-09-01
US7279496B2 (en) 2007-10-09
CA2445834A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU2003272316A1 (en) Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans
CA2953004C (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US7741343B2 (en) 6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
CZ20033195A3 (cs) Deriváty dihydroimidazo[4,5-e]indolu a 7H-pyrrolo[3,2-f]chinoxalinu jako ligandy nikotinacetylcholinového receptoru a/nebo serotonergické ligandy, způsob jejich přípravy a jejich použití
AU2002310904A1 (en) Dihydroimidazo[4,5-e]indole and 7H-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
AU2007238898A1 (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
EP2847193B1 (en) Heteroaryl compounds and methods of use thereof
AU2002257752A1 (en) 6H-OXAZOLO[4,5-E]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
JPH01172386A (ja) カルボリン誘導体、その製造方法およびカルボリン誘導体を有効成分とする線維素溶解剤
NO123430B (https=)
MD3649124T2 (ro) Compuși de fluoropiperidină ca antagoniști puri ai receptorului 5-HT6
CZ20032999A3 (cs) Ligandy nikotinacetylcholinového receptoru
HK1232222B (en) Aromatic heterocyclic derivatives and pharmaceutical applications thereof